Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Déwi Vernerey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6399-926X; OpenAlex author ID A5110469526. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 17

  1. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  3. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. Co-author DOI 10.1002/jcsm.13595↗
  4. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  5. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial. Co-author DOI 10.1097/sla.0000000000006468↗
  6. A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ stu… Co-author DOI 10.1186/s13014-024-02477-8↗
  7. Trimodal Peri Operative Prehabilitation for patient with Upper Oesogastric and Pancreatic cancer: study protocol for a multicenter, two- cohort, open-label, si… Co-author DOI 10.21203/rs.3.rs-4488963/v1↗
  8. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
  9. Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.683289↗
  10. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗
  11. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. Last author DOI 10.4251/wjgo.v12.i3.332↗
  12. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  13. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition o… Co-author DOI 10.1177/2050640618824910↗
  14. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODI… First author DOI 10.1186/s12885-018-4663-4↗
  15. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1093/jnci/djx037↗
  16. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
  17. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a mu… First author DOI 10.1186/s12885-016-2860-6↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cindy Neuzillet · 7 shared papers, 2017–2026 · strength 1.16
  2. Jean‐Baptiste Bachet · 5 shared papers, 2018–2026 · strength 0.90
  3. Pascal R. Hammel · 6 shared papers, 2016–2026 · strength 0.82
  4. Marc Hilmi · 3 shared papers, 2025–2026 · strength 0.70
  5. Christophe Borg · 6 shared papers, 2016–2024 · strength 0.63
  6. Lilian Schwarz · 3 shared papers, 2018–2024 · strength 0.54
  7. Angélique Vienot · 6 shared papers, 2016–2021 · strength 0.48
  8. Christophe Louvet · 4 shared papers, 2016–2026 · strength 0.45
  9. Anthony Turpin · 3 shared papers, 2020–2025 · strength 0.43
  10. Isabelle Trouilloud · 2 shared papers, 2021–2026 · strength 0.34
  11. Jerome F. Cros · 2 shared papers, 2019–2026 · strength 0.31
  12. Christelle d’Engremont · 4 shared papers, 2016–2021 · strength 0.31
  13. António Sá Cunha · 2 shared papers, 2018–2024 · strength 0.31
  14. Olivier Bouché · 2 shared papers, 2017–2026 · strength 0.30
  15. Benoı̂t Rousseau · 2 shared papers, 2017–2026 · strength 0.28
  16. Christophe Tournigand · 2 shared papers, 2017–2026 · strength 0.28
  17. Thierry André · 2 shared papers, 2016–2026 · strength 0.27
  18. Gaël S. Roth · 1 shared paper, 2026 · strength 0.24
  19. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  20. Victoire Cardot‐Ruffino · 1 shared paper, 2026 · strength 0.24
  21. Brice Chanez · 1 shared paper, 2026 · strength 0.24
  22. Nicolas Williet · 1 shared paper, 2026 · strength 0.24
  23. Pauline Parent · 1 shared paper, 2025 · strength 0.24
  24. Eva Ester Molina Beltran · 1 shared paper, 2024 · strength 0.23
  25. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.